Our office is currently working on various clinical studies. If you are interested in participating on any of the studies below please feel free to contact our research coordinator Suzette Zamora at 954-602-9723 Ext. 312 or click on the link below.

ARIEL 2– A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

MORPHOTEK- A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer

OVA 1 Post Marketing study: Patients over the age of 18 who have been diagnosed with an ovarian cyst. To participate the patient must be scheduled for surgery. Compensation for participation may be available.Uterine

Fibroid Study: Currently enrolling patients who are between the ages of 18 and 51 and have heavy bleeding caused by uterine fibroids. The patient must travel to the office and compensation is available if you qualify for the study

All of our clinical studies are able to be found in clinicaltrials. gov if you have any further questions or want more details regarding the study inclusion/exclusion criteria.